Clinical Trial

A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, Phase Ib clinical trial designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of the humanized monoclonal antibody EA5 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-20.
Trial Details
NCT Number NCT07256301
Lead Sponsor Shanghai Lanyi Therapeutics Co., Ltd.
Conditions PNH - Paroxysmal Nocturnal Hemoglobinuria
Enrollment 24 participants
Start Date 2024-01-03
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-14